Delivering quality therapy since 1901
  • Press releases

    EMA started the evaluation of Richter’s marketing authorisation application for cariprazine for the treatment of schizophrenia

    ​Gedeon Richter Plc. ("Richter") today announced that the European Medicines Agency (EMA) has accepted Richter's regulatory submission for cariprazine, a novel antipsychotic for the treatment of schizophrenia in adult patients. Cariprazine was discovered by Richter scientists and is licensed to Allergan (earlier Forest / Actavis), in the U.S. and Canada. Following its FDA approval in September 2015, the product has been recently launched in the USA under the trademark of VRAYLARTM for the treatment of both schizophrenia and bipolar mania.

  • in Focus

    Gynaecology

    Gynaecological therapy is a focus area for Richter. The company has several decades of unparalleled experience in this area. The first steroid experiments were conducted by the company’s founder, Gedeon Richter himself. Our company was the first pharmaceutical company to put a contraceptive on the Hungarian market, in 1966.

  • Central Nervous System
  • Cardiology
Loading...

​​​​​ ​​​​​ ​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​